Studies on the Cross‐Resistance of <i>Mycobacterium tuberculosis</i>, Strain H37Rv, to Aminoglycoside‐ and Peptide‐Antibiotics

Tsukamura, M; Matsumoto, Shoji

doi:10.1111/j.1348-0421.1980.tb02883.x

Cited by 7 publications

(3 citation statements)

References 7 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concerning injectable agents, cross-resistance is complex and evidence for it very limited. The most logical path on injectable use to avoid cross-resistance seems to be to start initially with capreomycin, then kanamycin and, finally, amikacin [56].…”

Section: Management Of Patients With Drug-resistant Tb: Lessons Learnmentioning

confidence: 99%

MDR-/XDR-TB management: what it was, current standards and what is ahead

Monedero¹,

Caminero²

2009

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Despite killing nearly 2 million people every year, TB is arguably the most neglected disease in terms of the funding and research it receives. In many ways, multidrug-resistant TB is a result of this disregard. In high-burden countries, not many improvements have been implemented in the diagnosis and treatment tools of TB since the 1960s. Following this period, fluoroquinolones, developed for other infections, are the only highly active new drugs against TB. Multidrug- and extensively drug-resistant TB is booming worldwide as a result of insufficient control measures. Furthermore, the prevalence of this disease is substantially facilitated by the HIV epidemic. After a deadly and well-reported extensively drug-resistant TB outbreak occurred in HIV-infected patients in South Africa, the threat of an untreatable TB epidemic is receiving increased attention internationally. Nevertheless, drug-resistant management has lacked research and funding over several decades and we are now faced with many controversial issues and little research-based evidence. There are no clinical trials comparing different treatments, and current management is based on personal experiences and agreement between experts. The major challenge for the next few years is to improve the evidence base in order to develop more rational recommendations that adequately address the current problem and avoid making a bad situation worse.

show abstract

Section: Management Of Patients With Drug-resistant Tb: Lessons Learnmentioning

confidence: 99%

MDR-/XDR-TB management: what it was, current standards and what is ahead

Monedero¹,

Caminero²

2009

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…The initial approach with regard to injectables is unclear. Probably, according to the limited literature available, the best choice of injectable in terms of cross resistance and toxicity could be the following sequence: capreomycin, then kanamycin and finally amikacin [Tsukamura and Mizuno, 1980;Tsukamura, 1969]; however, capreomycin is usually very expensive and difficult to acquire. Streptomycin is no longer recommended in MDR treatment mainly due to worldwide high levels of primary resistance and linked INH resistance [WHO, 2004[WHO, , 2008b.…”

Section: Ideal Regimenmentioning

confidence: 99%

Management of multidrug-resistant tuberculosis: an update

Monedero

Caminero

2010

Ther Adv Respir Dis

View full text Add to dashboard Cite

Multidrug-resistant tuberculosis (MDR-TB) is threatening control of TB in many parts of the world. As a result of limited treatment options, patients have a poor prognosis and low chances of cure. This situation can be exacerbated by HIV epidemics. In some cases, the risk exists of a real shift from susceptible to resistant strains. Despite its relevance, currently there are more contradictions and confusion surrounding MDR-TB than hard evidence. No randomized controlled trials have been performed and published evidence is limited. Rather than just the selection of expensive drugs, MDR-TB management requires well-structured programmes with a comprehensive approach, which involve the actions of a wide range of participants. Even with current investments in research and development, new drugs and vaccines will take many years to be applied in low and middle income countries. The most successful results will depend on the optimization of existing tools. The majority of the patients, even those with extensive patterns of bacilli resistance, have a possibility of cure if current clinical knowledge and effective logistics are applied. This paper is a critical review of current best practice regarding the diagnosis and treatment of MDR-TB.

show abstract

“…These drugs target bacterial ribosomes and historically there were reports of complex cross resistance patterns [3][4][5][6][7]. These drugs target bacterial ribosomes and historically there were reports of complex cross resistance patterns [3][4][5][6][7].…”

Section: The Evolution and Selection Of Drug Resistant Mycobacterium mentioning

confidence: 99%

The Evolution of Extensively Drug Resistant Tuberculosis (XDR-TB): History, Status and Issues for Global Control

Goldman

Plumley²,

Laughon

2007

IDDT

View full text Add to dashboard Cite

Tuberculosis (TB) is a devastating disease caused by Mycobacterium tuberculosis that killed an estimated 4000-5000 person each day during 2005. Although infections with drug sensitive strains can be effectively cured with a 6 to 9 month regimen of multiple antibiotics, the inability to deliver and complete appropriate courses of therapy on a global level has led to the selection of resistant strains over the past 50 years. The selection and spread of multiple drug resistant M. tuberculosis continued for decades leading to two operationally distinct forms of the disease, multiple drug resistant (MDR-TB) and extensively drug resistant (XDR-TB). The estimate for MDR-TB and XDR-TB cases for 2005 were 424,000 and 27,000 respectively, and the situation is worst in areas with high incidences of HIV infection. The outcome was predictable based on basic microbiological principles, and the resultant and future epidemic effectively modeled mathematically. This situation was brought to the forefront when an outbreak of XDR-TB occurred in Tugela Ferry, KwaZulu-Natal, South Africa, in 2005 and began to spread. Unfortunately, we do not know the true extent of XDR-TB globally. However, all signs point to an emerging epidemic of TB infections that will be difficult, if not impossible to cure. A few new drugs are in clinical trials, but it is too early to know the final outcome; some may fail, and none will be available for several years. The situation will continue to worsen unless more resources are made available to discover and deliver better treatment options.

show abstract

Studies on the Cross‐Resistance of Mycobacterium tuberculosis, Strain H37Rv, to Aminoglycoside‐ and Peptide‐Antibiotics

Cited by 7 publications

References 7 publications

MDR-/XDR-TB management: what it was, current standards and what is ahead

MDR-/XDR-TB management: what it was, current standards and what is ahead

Management of multidrug-resistant tuberculosis: an update

The Evolution of Extensively Drug Resistant Tuberculosis (XDR-TB): History, Status and Issues for Global Control

Contact Info

Product

Resources

About